Table of Contents Transforming Treatment Approaches From Lab Discovery to Clinical Impact Paper Summary In a nutshell A new blood test measuring eMTBR-tau243 accurately reflects the presence of tau ...

W ith two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the ...

Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...

The company behind the drug donanemab said it will ask regulators to reconsider the decision. View on euronews ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.

Over the past few months, investigative journalist Charles Piller has published—eg, in The Daily Mail, The New York Times, ...

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with ...

The research group led by Prof. Wang Chu from the College of Chemistry and Molecular Engineering at Peking University ...